NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Thanks. Possible further comparisons with the non-automated Provenge manufacturing:

Such automation of the initial stages of manufacturing DCVax® will greatly reduce the costs involved, including a more than 10-fold reduction in labor costs. For example, under current (first generation) processes, it takes 24 man hours to complete the initial manufacturing stage for 6 patients' vaccines. With the automated device, it takes only 2 man hours to complete the same work for 6 patients' vaccines. In addition, the need for certain high-cost materials is eliminated.

COGS for DCVax-L may actually be closer to $16K upon full-scale commercialization (and perhaps $25K-$30K initially) for 3 years of doses on average from a single manufacturing run.